Tokio Marine Asset Management Co. Ltd. Sells 616 Shares of Edwards Lifesciences Co. (NYSE:EW)

Tokio Marine Asset Management Co. Ltd. lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.2% in the 4th quarter, Holdings Channel reports. The firm owned 14,049 shares of the medical research company’s stock after selling 616 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $1,071,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST grew its position in shares of Edwards Lifesciences by 440.0% during the third quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock worth $243,173,000 after acquiring an additional 2,860,000 shares during the last quarter. AustralianSuper Pty Ltd purchased a new position in Edwards Lifesciences in the fourth quarter worth $168,519,000. Nordea Investment Management AB lifted its holdings in shares of Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after acquiring an additional 1,488,791 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Edwards Lifesciences by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after purchasing an additional 1,390,427 shares during the last quarter. Finally, FMR LLC lifted its position in shares of Edwards Lifesciences by 61.1% during the third quarter. FMR LLC now owns 3,111,385 shares of the medical research company’s stock worth $215,557,000 after purchasing an additional 1,179,637 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Oppenheimer upped their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Royal Bank of Canada boosted their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday, April 15th. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Finally, Citigroup boosted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $91.73.

Edwards Lifesciences Trading Down 2.2 %

Edwards Lifesciences stock traded down $1.92 during midday trading on Friday, reaching $86.09. The stock had a trading volume of 1,359,385 shares, compared to its average volume of 3,796,061. The firm has a market cap of $51.82 billion, a price-to-earnings ratio of 37.43, a PEG ratio of 4.39 and a beta of 1.05. The firm’s fifty day simple moving average is $90.27 and its two-hundred day simple moving average is $78.76. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the sale, the vice president now owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 1,715 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the transaction, the vice president now owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 in the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.